Mirdametinib (PD0325901), a highly selective MEK inhibitor, demonstrated a reduction in cell proliferation in vitro and prolonged mice survival in in vivo NF1-negative MPNST models6. The gene discussed is MAP2K7; the disease is malignant peripheral nerve sheath tumor.